Key result
FDA approves Widaplik fixed-dose combination of telmisartan, amlodipine, and indapamide for adult hypertension.
A new three-drug fixed-dose combination of telmisartan, amlodipine, and indapamide has been FDA-approved for managing adult hypertension.
Provides an additional triple-combination option; leaves open comparative effectiveness versus existing regimens.
The FDA has approved Widaplik (Azurity), a fixed-dose combination of the angiotensin receptor blocker (ARB) telmisartan, the dihydropyridine calcium channel blocker amlodipine, and the thiazide-like diuretic indapamide, for treatment of hypertension in adults. Telmisartan, amlodipine, and indapamide are also available alone and in various combinations for treatment of hypertension. Two three-drug combinations containing an ARB, amlodipine, and the thiazide diuretic hydrochlorothiazide (Exforge HCT and Tribenzor) have been available for years (see Table 1).
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in hypertension. Widaplik (telmisartan, amlodipine, and indapamide) was evaluated. The FDA has approved Widaplik, a fixed-dose combination of telmisartan, amlodipine, and indapamide, for the treatment of hypertension in adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: